Figure 3.

APOBEC mutational signature associated with immunotherapy benefit. A, Kaplan‐Meier survival analysis stratified by APOBEC mutational signatures status. The association between mutational activity of the APOBEC signature with progression‐free survival (B) and immune response status (C) were displayed in a forest plot. Age, sex, smoking status, histological type, PD‐L1, hypermutation, MMR, and smoking signature were likewise taken into account. Square data markers indicate estimated hazard ratios (B) and odds ratios (C). Error bars represent 95% CIs. APOBEC signature is associated with increased tumor mutation burden and neoantigen burden (D)